CAJ | 학술논문

目的：评价抗幽门螺杆菌（ Helicobacter pylori，H．pylori） HP1188蛋黄抗体（ HP1188-immunoglobulin yolk，HP1188-IgY）对BALB／c小鼠胃内H．pylori感染的治疗效果。方法：建立H．pylori感染BALB／c小鼠的动物模型，将建模成功的80只小鼠随机分为8组，每组10只。第1组（抗生素治疗组）、第2组（1 mg HP1188-IgY）、第3组（1 mg HP1188-IgY＋30％硫糖铝）、第4组（5 mg HP1188-IgY）、第5组（5 mg HP1188-IgY＋30％硫糖铝）、第6组（ PBS 对照组）和第7组（30％硫糖铝对照组）分别连续治疗10 d，每天1次；第8组间隔48 h 皮下注射2.5 mg HP1188-IgY，共2次；另10只正常小鼠为第9组（健康对照组）。处理完成2周后取各组小鼠胃组织作H．pylori 培养、快速尿素酶试验、PCR 检测H．pylori 特异性vacA和cagA及病理组织学检查，观察H．pylori 清除情况并进行评分。结果：在小鼠体内，灌胃（1 mg HP1188-IgY＋30％硫糖铝）即可有效治疗H．pylori 感染引起的胃黏膜损害，其治疗效果与抗生素相似。结论：成功构建了H．pylori 感染的BALB／c 小鼠模型，选择30％硫糖铝为抗体保护剂，经口服HP1188-IgY可抑制小鼠胃内H．pylori 感染。
목적：평개항유문라간균（ Helicobacter pylori，H．pylori） HP1188단황항체（ HP1188-immunoglobulin yolk，HP1188-IgY）대BALB／c소서위내H．pylori감염적치료효과。방법：건립H．pylori감염BALB／c소서적동물모형，장건모성공적80지소서수궤분위8조，매조10지。제1조（항생소치료조）、제2조（1 mg HP1188-IgY）、제3조（1 mg HP1188-IgY＋30％류당려）、제4조（5 mg HP1188-IgY）、제5조（5 mg HP1188-IgY＋30％류당려）、제6조（ PBS 대조조）화제7조（30％류당려대조조）분별련속치료10 d，매천1차；제8조간격48 h 피하주사2.5 mg HP1188-IgY，공2차；령10지정상소서위제9조（건강대조조）。처리완성2주후취각조소서위조직작H．pylori 배양、쾌속뇨소매시험、PCR 검측H．pylori 특이성vacA화cagA급병리조직학검사，관찰H．pylori 청제정황병진행평분。결과：재소서체내，관위（1 mg HP1188-IgY＋30％류당려）즉가유효치료H．pylori 감염인기적위점막손해，기치료효과여항생소상사。결론：성공구건료H．pylori 감염적BALB／c 소서모형，선택30％류당려위항체보호제，경구복HP1188-IgY가억제소서위내H．pylori 감염。
AIM:To evaluate the effects of treatment with HP 1188-immunoglobulin yolk ( HP1188-IgY) on Helicobacter pylori ( H.pylori)-infected gastritis in BALB/c mice.METHODS:BALB/c mice were used to establish an animal model of H.pylori-infected gastritis, and the mice were divided into 8 groups (10 mice per group).Oral antibiotics were used in group 1, 1 mg HP1188-IgY in group 2, 1 mg HP1188-IgY plus 30%sucralfate in group 3, 5 mg HP1188-IgY in group 4, 5 mg HP1188-IgY plus 30%sucralfate in group 5, PBS in group 6, and 30% sucralfate in group 7 with the treatment once per day for 10 d;and 2.5 mg HP1188-IgY was injected hypodermically twice with a 48-h interval in group 8.Another 10 mice were used as normal control in group 9.The planting of bacteria in the stomach was assayed by bacteri-al culture, rapid urease test, PCR and pathological sectioning .RESULTS:Intragastric administration with 1 mg HP1188-IgY plus 30%sucralfate per day effectively cured the injury of gastric mucosa caused by H.pylori infection, and the effect has no significant difference compared with antibiotics (P>0.05).CONCLUSION:We establish a BALB/c mouse mod-el infected with H.pylori successfully.Sucralfate (30%) is an ideal protectant for HP1188-IgY, which might decrease H. pylori infection in the stomach of BALB/c mice by oral inoculation .